Next Article in Journal
Racial Disparities-Associated COVID-19 Mortality among Minority Populations in the US
Previous Article in Journal
Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection
 
 
Review

A Panel of Broad-Spectrum Antivirals in Topical Ophthalmic Medications from the Drug Repurposing Approach during and after the Coronavirus Disease 2019 Era

1
Clinica Oculistica, San Giovanni di Dio Hospital, Azienda Ospedaliera Universitaria di Cagliari, 09124 Cagliari, Italy
2
Department of Surgical Sciences, Eye Clinic, University of Cagliari, 09124 Cagliari, Italy
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(8), 2441; https://doi.org/10.3390/jcm9082441
Received: 5 June 2020 / Revised: 15 July 2020 / Accepted: 27 July 2020 / Published: 30 July 2020
(This article belongs to the Section Ophthalmology)
The coronavirus disease 2019 (COVID-19) represents a global concern of public health caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its clinical manifestations are characterized by a heterogeneous group of symptoms and pictures (ranging from asymptomatic to lethal courses). The prevalence of conjunctivitis in patients with COVID-19 is at present controversial. Although it has been reported that only 0.9% developed signs of conjunctivitis, other report indicates that up to 31.6% of hospitalized patients had conjunctivitis. Considering the widespread use of topical ophthalmic medications (e.g., eye drops) by the general population, for various reasons (e.g., artificial tears, anti-glaucoma medications, topical antibiotics, etc.), the existence of their side effects as antiviral action should be investigated in-depth because it could possibly explain the aforementioned controversial data and represent a potential antiviral treatment for SARS-CoV-2 replication/diffusion on the ocular surface. Here, we discuss and elucidate the antiviral side effect of many eye drops and ophthalmic ointments commonly used for others purposes, thus showing that these secondary effects (not to be confused with the ‘adverse effects’) might be of primary importance in a number of viral infections (e.g., those for which there is no validated treatment protocol), according to a drug repurposing approach. Some active ingredients or excipients described here have activity against other types of viruses, thus suggesting potential broad-spectrum applications. View Full-Text
Keywords: coronavirus disease 2019 (COVID-19); coronavirus; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); eye drop; therapy; treatment; antiviral; repurposing; drug; ocular surface coronavirus disease 2019 (COVID-19); coronavirus; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); eye drop; therapy; treatment; antiviral; repurposing; drug; ocular surface
MDPI and ACS Style

Napoli, P.E.; Mangoni, L.; Gentile, P.; Braghiroli, M.; Fossarello, M. A Panel of Broad-Spectrum Antivirals in Topical Ophthalmic Medications from the Drug Repurposing Approach during and after the Coronavirus Disease 2019 Era. J. Clin. Med. 2020, 9, 2441. https://doi.org/10.3390/jcm9082441

AMA Style

Napoli PE, Mangoni L, Gentile P, Braghiroli M, Fossarello M. A Panel of Broad-Spectrum Antivirals in Topical Ophthalmic Medications from the Drug Repurposing Approach during and after the Coronavirus Disease 2019 Era. Journal of Clinical Medicine. 2020; 9(8):2441. https://doi.org/10.3390/jcm9082441

Chicago/Turabian Style

Napoli, Pietro Emanuele, Lorenzo Mangoni, Pietro Gentile, Mirco Braghiroli, and Maurizio Fossarello. 2020. "A Panel of Broad-Spectrum Antivirals in Topical Ophthalmic Medications from the Drug Repurposing Approach during and after the Coronavirus Disease 2019 Era" Journal of Clinical Medicine 9, no. 8: 2441. https://doi.org/10.3390/jcm9082441

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop